- Home
- HDL vs ATAI Comparison
HDL vs ATAI Comparison
Compare HDL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- ATAI
- Stock Information
- Founded
- HDL 2016
- ATAI 2018
- Country
- HDL Singapore
- ATAI Netherlands
- Employees
- HDL N/A
- ATAI N/A
- Industry
- HDL Restaurants
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- ATAI Health Care
- Exchange
- HDL Nasdaq
- ATAI Nasdaq
- Market Cap
- HDL 1.1B
- ATAI 1.1B
- IPO Year
- HDL 2024
- ATAI 2021
- Fundamental
- Price
- HDL $17.81
- ATAI $5.23
- Analyst Decision
- HDL
- ATAI Strong Buy
- Analyst Count
- HDL 0
- ATAI 4
- Target Price
- HDL N/A
- ATAI $13.75
- AVG Volume (30 Days)
- HDL 3.1K
- ATAI 5.8M
- Earning Date
- HDL 11-24-2025
- ATAI 11-12-2025
- Dividend Yield
- HDL N/A
- ATAI N/A
- EPS Growth
- HDL 197.81
- ATAI N/A
- EPS
- HDL 0.09
- ATAI N/A
- Revenue
- HDL $805,433,000.00
- ATAI $2,309,000.00
- Revenue This Year
- HDL $12.52
- ATAI $712.99
- Revenue Next Year
- HDL $12.03
- ATAI N/A
- P/E Ratio
- HDL $21.89
- ATAI N/A
- Revenue Growth
- HDL 9.65
- ATAI 510.85
- 52 Week Low
- HDL $15.54
- ATAI $1.03
- 52 Week High
- HDL $30.00
- ATAI $5.97
- Technical
- Relative Strength Index (RSI)
- HDL 34.79
- ATAI 59.26
- Support Level
- HDL $17.99
- ATAI $4.99
- Resistance Level
- HDL $19.16
- ATAI $5.44
- Average True Range (ATR)
- HDL 0.25
- ATAI 0.34
- MACD
- HDL -0.02
- ATAI -0.02
- Stochastic Oscillator
- HDL 3.13
- ATAI 48.42
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.